Cryptogenic Organizing Pneumonia: In the Setting of Staphylococcus
aureus Endocarditis
To the Editor,
Organizing pneumonia (OP) is a rare, diffuse lung disease process
associated with nonspecific symptoms, radiologic abnormalities, and
pulmonary function test (PFT) abnormalities. The histopathologic
pattern is characterized by patchy filling of the lung alveoli and
respiratory bronchioles with loose plugs of granulation tissue. Although
formerly described in the context of pulmonary infection, the condition
was recognized as an independent entity starting in the
1980s.[1] There are a variety of potential
etiologies that culminate in the development of OP. However, when no
cause is specifically identified, OP is classified as cryptogenic
organizing pneumonia (COP), previously described as bronchiolitis
obliterans with organizing pneumonia (BOOP).[2]
In COP, both genders are equally affected with the mean age of onset
between 50 and 60 years old. The relative prevalence of COP is
approximately twice as high in non-smoking individuals when compared to
those that smoke.[3] Symptoms typically present as
a mild flu-like illness with cough, fever, malaise, and dyspnea with
risk for rapid progression requiring invasive
ventilation[4] or even extracorporeal membrane
oxygenation (ECMO)[2]. However, symptoms can
regress quickly with steroid therapy. Chest radiologic findings can be
variable and laboratory evaluations non-specific; a lung biopsy for
histopathologic analysis is usually required to establish the definitive
diagnosis.[4]
Discussed is a case of a 14-year-old female with no significant past
medical history, who presented to the hospital for progressive dyspnea
and worsening cough following a recent discharge related
to methicillin-susceptible Staphylococcus aureus endocarditis.
During her initial endocarditis hospital course, she required surgical
procedures to repair and ultimately replace her mitral valve. A 6-week
course of Nafcillin was initiated and she was discharged home a month
later with documented complaints of a mild cough at time at
discharge. Her chest X-ray at discharge revealed small bilateral pleural
effusions and she was able maintained oxygen saturations above 90%
without supplemental oxygen.
Upon re-admission one week after her initial discharge, she required
high-flow nasal canula at 8 liters, 30% FiO2 with a
chest X-ray revealing stable pleural effusions, but with progressive
alveolar opacities involving the right middle and lower lung lobes with
an interstitial component. Due to concern for infectious pneumonia, the
patient was initiated on 24-hour broad spectrum antibiotics with
linezolid and gentamicin, in addition to ongoing nafcillin course.
Within the first 48 hours of admission, a large left ventricular
pseudoaneurysm was identified that required urgent repair. Following
repair, her antibiotic coverage was narrowed back to nafcillin as
monotherapy. Unfortunately, she remained unable to wean off
respiratory support. Repeated chest imaging showed progressive worsening
of her right sided opacities.
Computed tomography (CT) angiography of the chest demonstrated evidence
of severe right-sided airspace disease [Figure 1]. Right upper lobe
segments showed patchy ground glass opacities intermixed with
consolidations and mild interlobular septal thickening at the apex.
There was near complete consolidation of the right middle lobe, as well
as nonconfluent consolidative opacification with scattered ovoid
lucencies throughout the right lower lobe. These findings were
nonspecific, leaving a broad differential including: atelectasis, edema,
or other airspace infiltrate, such as infectious pneumonia. Antibiotics
were again broadened to include ceftriaxone. Despite this, a cavitary
lesion developed on the standard radiograph one week after initial CT
angiography. Repeat chest CT confirmed the presence of a cavitary lesion
and demonstrated new development of left-sided ground glass opacities
[Figure 1].
Bronchoscopy with BAL revealed a neutrophil (40%) and monocyte (42%)
predominance. Her comprehensive infectious workup remained unremarkable.
A wedge lung biopsy of her right upper and lower lobe was obtained via
video-assisted thoracoscopic surgery (VATS). Histology showed extensive
organizing pneumonia with extension into the bronchioles [Figure 1].
There were increases in intra-alveolar hemosiderin-laden macrophages and
hyperplastic type II pneumocytes with organizing pleural fibrin. No
evidence of vasculitis or capillaritis was visualized.
Upon confirmation of organizing pneumonia, the patient was started on
intravenous methylprednisolone at a dose of 125 mg every 6 hours for 5
days, followed by a prolonged steroid taper. She received 2 doses of
intravenous immunoglobulin (IVIG) after the initiation of steroids. In
an effort to address the obliterative process of the airways, she was
started on FAM therapy with inhaled fluticasone (110 mcg 2 puffs twice
daily), azithromycin (500 mg MWF), and montelukast (10 mg nightly). The
patient completed her 6-week course of nafcillin for her endocarditis
and tolerated weaning off her respiratory support.
Prior to discharge, she was evaluated by Rheumatology and Immunology for
potential causes of organizing pneumonia. Her laboratory workup included
ANA, ANCA, PR3 antibodies, IgA, IgG, IgM, thyroid studies, and
rheumatoid factor, with all results within normal limits. Genetic
testing for connective tissue disease was negative. The patient was
discharged home with close follow-up and ongoing steroid wean over
8-weeks. She participated in cardiopulmonary rehabilitation for 8 weeks
and was weaned off steroids without difficulty. Pulmonary function
testing (PFT) was obtained 4 months following the initial diagnosis
and resulted in a forced expiratory volume in one second (FEV1) of 57%
predicted with a total lung capacity (TLC) of 52% predicted. After one
year of pharmacologic and mechanical therapies, the FEV1 improved to
73% predicted and the TLC to 78% predicted with a normal corrected
diffusion capacity of the lung for carbon monoxide (DLCO) at 104%
predicted. She resumed competitive tennis with reported
excellent exercise endurance for 3 hours of continuous
activity.
This unique case highlights a rare condition that is even rarer in the
pediatric population. Clinical presentation can be severe. Radiologic
findings tend to be diverse, but typically present with bilateral
opacities that are patchy or diffuse and consolidative in the presence
of normal lung volumes, often requiring high resolution CT scan to
determine the extent and severity of disease.[6]Laboratory workup is often nonspecific, with frequent elevation of
inflammatory markers such as C-reactive protein, erythrocyte
sedimentation rate, and leukocyte count. Lung biopsy is often
required to obtain the definitive diagnosis and initiate
appropriate therapy. The delay in diagnosis and treatment may lead to
clinical deterioration and permanent injury to the lungs.
The mainstay of COP therapy is corticosteroids, usually resulting in
rapid clinical improvement and clearing of opacities on chest imaging.
In adult patients, adjunctive FAM therapy may halt pulmonary decline of
associated obliterative bronchiolitis.[5] The
combined therapy may permit a reduction in steroid exposure,
collectively leading to better health with an improved quality of life.
Relapses are documented in less than 25% of cases. When occurring, they
are usually within the first year of diagnosis and while tapering
glucocorticoids. Patients respond well to resuming or increasing
glucocorticoid treatment. However, for patients who are unable to
discontinue steroids, glucocorticoid sparing agents, such as
mycophenolate mofetil, can be considered.[6]
Although COP is idiopathic by definition, it is important to investigate
each diagnosed case for potential causes, such as iatrogenic from
radiation or known causative medications [1],
connective tissue diseases, inflammatory bowel disease, malignancies,
history of lung transplant or bone marrow graft. OP may present weeks to
months before other signs of connective tissue disorders and therefore
the patient should undergo serologic testing for these
diseases.[6] In the case presented, the specific
etiology was unyielding and so remains cryptogenic in nature. This
patient’s symptoms quickly improved following the use of steroids and
tolerated tapering off completely without relapse one year out from
initial diagnosis.
References:
- Cottin V, Cordier JF. Cryptogenic organizing pneumonia. Semin Respir
Crit Care Med. 2012 Oct;33(5):462-75.
- Sayad E, Coleman RD, Silva-Carmona MD. Diagnosis and treatment of
cryptogenic organizing pneumonia in a child on ECMO. Pediatr Pulmonol.
2020 Jan;55(1):20-22.
- Baque-Juston M, Pellegrin A, Leroy S, Marquette CH, Padovani B.
Organizing pneumonia: what is it? A conceptual approach and pictorial
review. Diagn Interv Imaging. 2014 Sep;95(9):771-7
- Drakopanagiotakis F, Paschalaki K, et al. Cryptogenic and secondary
organizing pneumonia: clinical presentation, radiographic findings,
treatment response, and prognosis. Chest. 2011 Apr;139(4):893-900.
- Williams KM, Cheng GS, et al. Fluticasone, Azithromycin, and
Montelukast Treatment for New-Onset Bronchiolitis Obliterans Syndrome
after Hematopoietic Cell Transplantation. Biol Blood Marrow
Transplant. 2016 Apr;22(4):710-716.
- King TE Jr, Lee JS. Cryptogenic Organizing Pneumonia. N Engl J Med.
2022 Mar 17;386(11):1058-1069.
Eric S. Mull, DOab, Sarah Cohen,
MDabe, Ashish George, DOa,
Katelyn Krivchenia, MDab, Stephen Druhan,
MDc, Peter B. Baker III, MDd,
Benjamin Kopp, MDab
aDivision of Pulmonary Medicine;bDepartment of Pediatrics;cDepartment of Radiology;
dDepartment of Pathology and Laboratory Medicine
eDivision of Pulmonary, Critical Care, and Sleep
Medicine, Ohio State University Wexner Medical Center
The Ohio State University
Columbus, Ohio
Institution: Nationwide Children’s Hospital; Columbus, OH
Funding Source: None
Financial Disclosure: None
Conflicts of Interest: None